Long-acting somatostatin analogues decrease blood transfusion requirements in patients with refractory...

Area of Science:

• Gastroenterology
• Internal Medicine
• Pharmacology

Background:

• Gastrointestinal angiodysplasias (GIADs) are a common cause of recurrent gastrointestinal bleeding.
• Endoscopic treatments for GIADs are not always effective, leading to refractory bleeding.

Purpose of the Study:

• To evaluate the efficacy of long-acting somatostatin analogues in managing refractory bleeding from GIADs.
• To assess the impact on blood transfusion requirements, bleeding frequency, and hemoglobin levels.

Main Methods:

• A cohort of 15 patients with recurrent GIAD bleeding received somatostatin analogue treatment for at least 6 months.
• Efficacy was measured by comparing transfusion needs, bleeding episodes, and hemoglobin levels during treatment versus a 6-month pre-treatment period.

Main Results:

• Somatostatin analogue treatment led to a significant decrease in blood transfusions (median 2 vs. 10, P < 0.001).
• The percentage of patients experiencing bleeding events dropped from 73% to 20% (P = 0.01).
• Mean hemoglobin levels significantly increased during treatment (median 10 g/dL vs. 7 g/dL, P < 0.001).

Conclusions:

• Long-acting somatostatin analogues effectively reduce transfusion needs in patients with refractory GIAD bleeding.
• Treatment improved bleeding control and hemoglobin levels with no reported side effects leading to discontinuation.
• Somatostatin analogues offer a viable management option for chronic bleeding due to GIADs.